Blood tests for Alzheimer's disease in people with memory concerns seen by family doctors
Tests a blood marker, ptau217, for Alzheimer's disease in people with cognitive concerns.
Plain-language title generated from the registry record
Registry title: Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.
Key facts
- Where
- Leuven, BelgiumSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 85 years old?
Source: NCT07666113, who can take part
Where in Belgium
- UZ Leuven/KU LeuvenLeuven, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitaire Ziekenhuizen KU Leuven
- Trial code
- NCT07666113
- Record updated
- 24 June 2026
- Original description
The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217/Aβ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns.Read full original descriptionShow less
The Diagnostic Validity and Clinical Impact of Blood-based Biomarkers for the Diagnosis of Alzheimer's Disease at the Primary Care Level.
The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217/Aβ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns.
Participants will provide a blood sample for biomarker testing and undergo clinical assessments as part of diagnostic evaluation.
Inclusion: Patients between 55 and 85 years old who consult their PCP due to concerns about their cognitive status.
Exclusion: Concomitant medications that would interfere with cognitive assessments; A prior diagnosis of AD and related disorders or other neurodegenerative disease; Comorbidities that would interfere with study cooperation or interpretability of study results (for instance substance abuse or cardiac, renal or hepatic failure).